{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:52:25Z","timestamp":1769086345102,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2924,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Korea","award":["NCT00171080"],"award-info":[{"award-number":["NCT00171080"]}]},{"name":"Novartis Korea","award":["NCT00171080"],"award-info":[{"award-number":["NCT00171080"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although clinical guidelines advocate the use of the highest tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after acute myocardial infarction (MI), the optimal dosing or the risk\u2013benefit profile of different doses have not been fully identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this multicentre trial, 495 Korean patients with acute ST segment elevation MI and subnormal left ventricular (LV) ejection fraction (&amp;lt;50%) were randomly allocated (2:1) to receive maximal tolerated dose of valsartan (titrated up to 320 mg\/day, n = 333) or low-dose valsartan (80 mg\/day, n = 162) treatment. The primary objective was to assess the changes in echocardiographic parameters of LV remodelling from baseline to 12 months after discharge. After treatment, end-diastolic LV volume (LVEDV) decreased significantly in the low-dose group, but the difference in LVEDV changes was insignificant between the maximal-tolerated-dose and low-dose groups. End-systolic LV volume decreased significantly in both groups, to a similar degree between groups. LV ejection fraction rose significantly in both study groups, to a similar degree. Changes in plasma levels of neurohormones were also comparable between the two groups. Drug-related adverse effects occurred more frequently in the maximal-tolerated-dose group than in the low-dose group (7.96 vs. 0.69%, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the present study, treatment with the maximal tolerated dose of valsartan did not exhibit a superior effect on post-MI LV remodelling compared with low-dose treatment and was associated with a greater frequency of adverse effect in Korean patients. Further study with a sufficient number of cases and statistical power is warranted to verify the findings of the present study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12249","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T06:34:42Z","timestamp":1516170882000},"page":"354-363","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of a Dose of the Angiotensin Receptor Blocker Valsartan on Post-Myocardial Infarction Ventricular Remodelling"],"prefix":"10.1093","volume":"5","author":[{"given":"Kyungil","family":"Park","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Dae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Sik","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Catholic University of Daegu , Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dongkang Medical Center , Ulsan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Ho","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Gon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Ulsan University Hospital , Ulsan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Daedong Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Ho","family":"Hur","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Keimyung University Hospital , Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Inje University, Busan Paik Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Hyun","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Sungkyunkwan University, Samsung Changwon Hospital , Changwon ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek-Jong","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Busan National University Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Sun","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital , Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Gyeongsang University Hospital , Jinju ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byungcheon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Daegu Fatima Hospital , Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Hyung","family":"Bae","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Bong Seong Memorial Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"2026012115120431800_ehf212249-bib-0001","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026012115120431800_ehf212249-bib-0002","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026012115120431800_ehf212249-bib-0003","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"2026012115120431800_ehf212249-bib-0004","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"2026012115120431800_ehf212249-bib-0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012115120431800_ehf212249-bib-0006","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0007","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Developed in collaboration with the Heart Failure Association (HFA) of the ESC","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115120431800_ehf212249-bib-0008","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.94.4.690","article-title":"Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction","volume":"94","author":"Benedict","year":"1996","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0009","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2143\/AC.55.1.2005711","article-title":"Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficiency Patients Study (CHIPS)","volume":"55","author":"Clement","year":"2000","journal-title":"Acta Cardiol"},{"key":"2026012115120431800_ehf212249-bib-0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/euhj.1997.0839","article-title":"Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison","volume":"19","author":"The NETWORK Investigators","year":"1998","journal-title":"Eur Heart J"},{"key":"2026012115120431800_ehf212249-bib-0012","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2026012115120431800_ehf212249-bib-0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1745-6215-12-247","article-title":"The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial","volume":"12","author":"Cho","year":"2011","journal-title":"Trials"},{"key":"2026012115120431800_ehf212249-bib-0014","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"American Society of Echocardiography's Guidelines and Standard Committee: European Association of Echocardiography","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012115120431800_ehf212249-bib-0015","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","article-title":"Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction","volume":"111","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0016","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/01.CIR.94.9.2285","article-title":"Medical therapy can improve the biological properties of the chronically failing heart","volume":"94","author":"Eichhorn","year":"1996","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"2026012115120431800_ehf212249-bib-0018","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0735-1097(97)00012-0","article-title":"Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease","volume":"29","author":"Doughty","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026012115120431800_ehf212249-bib-0019","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(01)06660-0","article-title":"Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure","volume":"358","author":"Campbell","year":"2001","journal-title":"Lancet"},{"key":"2026012115120431800_ehf212249-bib-0020","first-page":"143","article-title":"Effects of ACE inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure","volume":"51","author":"Khattar","year":"2003","journal-title":"Minerva Cardioangiol"},{"key":"2026012115120431800_ehf212249-bib-0021","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012115120431800_ehf212249-bib-0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mcp.2002.121425","article-title":"Comparative angiotensin II receptor blockade in healthy volunteers","volume":"71","author":"Maillard","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"2026012115120431800_ehf212249-bib-0023","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/hr.2010.108","article-title":"Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(\u22121)","volume":"33","author":"Saikawa","year":"2010","journal-title":"Hypertens Res"},{"key":"2026012115120431800_ehf212249-bib-0024","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.166.6.659","article-title":"Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome. Results of the randomized perindopril and remodeling in elderly with acute myocardial infarction","volume":"166","author":"The PREAMI Investigators","year":"2006","journal-title":"Arch Intern Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/2\/354\/66137330\/eschf_5_2_354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/2\/354\/66137330\/eschf_5_2_354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:16:03Z","timestamp":1769026563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/5\/2\/354\/8403943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,17]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12249","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"2017-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}